Rubicon Research Limited
Rubicon Research Limited (RUBICON) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
rubicon.co.in(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 412 Cr | 476 Cr | 514 Cr | 534 Cr |
| Operating expenses (approx.) | 318 Cr | 367 Cr | 395 Cr | 405 Cr |
| EBITDA | 94 Cr | 108 Cr | 119 Cr | 129 Cr |
| OPM % | 22.9% | 22.7% | 23.1% | 24.2% |
| Other income | 0.70 Cr | 4 Cr | 3 Cr | 6 Cr |
| Interest | 11 Cr | 10 Cr | 10 Cr | 9 Cr |
| Depreciation | 12 Cr | 12 Cr | 12 Cr | 15 Cr |
| Profit before tax | 72 Cr | 91 Cr | 99 Cr | 110 Cr |
| Tax % | 24.9% | 19.6% | 22.2% | 23.2% |
| Net profit | 54 Cr | 73 Cr | 77 Cr | 85 Cr |
| EPS (₹) | ₹3.49 | ₹4.46 | ₹4.66 | ₹5.13 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2026 | TTM |
|---|---|---|
| Sales | 1,754 Cr | Sign in for TTM |
| Operating expenses (approx.) | 1,354 Cr | Sign in for TTM |
| EBITDA | 400 Cr | Sign in for TTM |
| OPM % | 22.8% | Sign in for TTM |
| Other income | 8 Cr | Sign in for TTM |
| Interest | 42 Cr | Sign in for TTM |
| Depreciation | 45 Cr | Sign in for TTM |
| Profit before tax | 321 Cr | Sign in for TTM |
| Tax % | 23.0% | Sign in for TTM |
| Net profit | 247 Cr | Sign in for TTM |
| EPS (₹) | ₹15.52 | Sign in for TTM |
| Dividend payout % | 0.1% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2026 |
|---|---|
| Equity capital | 17 Cr |
| Reserves | 1,272 Cr |
| Borrowings | 259 Cr |
| Other liabilities | 779 Cr |
| Total liabilities | 2,327 Cr |
| Fixed assets (net) | 467 Cr |
| CWIP | 40 Cr |
| Investments | 27 Cr |
| Inventories | 729 Cr |
| Trade receivables | 509 Cr |
| Cash & bank | 186 Cr |
| Other assets | 369 Cr |
| Total assets | 2,327 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2026 |
|---|---|
| Cash from operating activity | 205 Cr |
| Cash from investing | -410 Cr |
| Cash from financing | 283 Cr |
| Net cash flow | 81 Cr |
| Free cash flow (OCF − Capex) | -24 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2026 |
|---|---|
| ROCE % | 23.4% |
| ROE % | 19.1% |
| Debtor days | 106 |
| Inventory days | 431 |
| Days payable | 223 |
| Cash conversion cycle | 314 |
| Debt / equity | 0.20 |
| Current ratio | 2.01 |
| Net debt / EBITDA | 0.18 |
Compare with peers
Loading peers…